Strategic Acquisition Tear Film Innovations was acquired by Alcon in December 2018, indicating strong strategic value and potential access to Alcon’s distribution network, regulatory expertise, and clinical validation for eye care devices.

Focus on Dry Eye The iLux device targets evaporative dry eye and meibomian gland dysfunction, a large and growing segment in ophthalmology, suggesting opportunity to upsell to clinics expanding dry eye management and MGD treatment offerings.

Commercial Readiness As a commercial stage company with a discrete medical device, there is potential to scale through partnerships with large ophthalmic distributors and eye care practices, leveraging existing branding and clinical demonstrations.

Funding Momentum Past funding rounds including an $8.5M Series B and involvement from Visionary Ventures Fund and Bluestem Capital indicate investor confidence and may facilitate co-investment or channel partnerships to accelerate sales.

Cost-Effective Platform The iLux system combines disposables with a smart tip and a single-button operation, presenting opportunities for service models, consumable-based revenue, and recurring orders with clinics seeking efficient, easy-to-use devices.